Welcome to CardioRenal

Digital therapeutics for chronic cardiovascular disease

CardioRenal is a company that develops and markets digital therapeutics solutions for chronic disease management.

We want to improve chronic patient treatment at home

CardioRenal uses the most advanced technologies to develop digital therapeutic solutions allowing chronic patient at home to benefit from a personalized medicine

Our shared vision is that now is the time to help chronic patients to have a better healthcare delivery at home.

“ Long term patient engagement in their disease management is within our reach ”

Maurice Berenger,

Co-founder, CEO of CardioRenal

Chronic kidney disease

Cardiorenal’ s mission is to improve chronic patient care with our unique digital therapeutic solutions relying on blood biomarkers monitored at home

Around 700 million

People with chronic kidney disease in the world1, with likely many more still undiagnosed

Expenses

2- 3% of annual heathcare budget spent in end stage renal disease treatment2

Treatment

Up to 40-50% with CKD may be affected by hyperkalemia and have under-dosed life saving drugs treatment3,4

Cardiovascular

Associated events account four up to 30% of death in patients with CKD5

  1. Bikbov B et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet 2020; 395(10225):709–33
  2. Bello AK et al. Global Kidney Health Atlas: A report by the International Society of Nephrology on the current state of organization and structures for kidney care across the globe. Brussels, Belgium: International Society of Nephrology; 2017. Available from: URL: www.theisn.org/global-atlas.
  3. National Kidney Foundation. Facts About High Potassium in Patients with Kidney Disease [cited 16 Oct 2020]. Available from: URL: https://www.kidney.org/atoz/content/hyperkalemia/facts.
  4. Pecoits-Filho R et al. Prescription of renin-angiotensin-aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care. J Clin Hypertens (Greenwich). 2019;21(7):991-1001.
  5. Thompson S et al. Cause of Death in Patients with Reduced Kidney Function. J Am Soc Nephrol 2015; 26(10):2504–11.
Product under development not approved for sales

TENOR ©

An integrated digital therapeutic solution based on blood potassium monitoring at home.

CRIS ©

A software suite developed for any entity (company, hospital, etc.) wishing to have a ready-made and versatile remote patient monitoring tool.

Product under development not approved for sales

Product under development not approved for sales

SOPRANO ©

An Evidence-based digital therapeutic solution intended to improve the treatment of Heart Failure patients at home.

Microfluidics

Ensure the transport and delivery of the blood sample to the biosensors in a reproducible manner

Electrochemistry

Used to transform blood ions concentrations in electrical signals that can be analysed

Artificial Intelligence

Leverage gathered biomarkers data and patient history to sharpen medical care and refine clinical decisions.

Contact Us

Our team

A team of high-level scientists passionate about helping to improve the health of a large number of chronic patients around the world.

Maurice Berenger

Chief Executive Officer

Guilhem Henrion

Chief Technical Officer

Julie Papillon

Operations Director

Daphné Laporte

QRA Manager

Moez Karoui

Cloud Application Manager

David Lefebvre

Industrialization Manager

Fengjuan WANG

Innovation Manager

Gabriel Lemercier

R&D project leader

David Rabaud

Industrialisation project leader

Board of directors

Maurice Berenger

Chief Executive Officer

Faiez Zannad

Founder

Didier Miraton

Independent Member

Our Partenrs

Awards

Plan de Relance – Résilience

French IoT Start-up Communauté

EIT Health Ulabs

Concours d’innovation – i-Nov

Seal of Excellence

Be Est Projet à venir

headquarter

29 Rue des grandes arcades, 67000 Strasbourg, FRANCE

Email

contact@cardio-renal.com